Leonardo Brunetti
A5049882025- Cancer Immunotherapy and Biomarkers
- Diabetes Treatment and Management
- Pancreatic and Hepatic Oncology Research
- Neutropenia and Cancer Infections
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Metabolism, Diabetes, and Cancer
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Immune cells in cancer
- Economic and Financial Impacts of Cancer
- Inflammatory Biomarkers in Disease Prognosis
- Lung Cancer Treatments and Mutations
- Renal Transplantation Outcomes and Treatments
- Gastric Cancer Management and Outcomes
- Ferroptosis and cancer prognosis
- Medication Adherence and Compliance
- Diabetes and associated disorders
- Lung Cancer Research Studies
- Chronic Lymphocytic Leukemia Research
- Advanced Breast Cancer Therapies
- Lung Cancer Diagnosis and Treatment
- Cancer, Stress, Anesthesia, and Immune Response
- Hepatocellular Carcinoma Treatment and Prognosis
- Drug-Induced Hepatotoxicity and Protection
- RNA modifications and cancer
Università Campus Bio-Medico
2022-2025
Campus Bio Medico University Hospital
2023-2025
Imperial College London
2025
Hammersmith Hospital
2025
Abstract Purpose: No evidence exists as to whether type 2 diabetes mellitus (T2DM) impairs clinical outcome from immune checkpoint inhibitors (ICI) in patients with solid tumors. Experimental Design: In a large cohort of ICI recipients treated at 21 institutions June 2014 2020, we studied on glucose-lowering medications (GLM) for T2DM had shorter overall survival (OS) and progression-free (PFS). We used targeted transcriptomics subset explore differences the tumor microenvironment (TME) or...
Immune-related liver injury (irLI) is commonly observed in patients with cancer treated immune checkpoint inhibitors (ICIs). We aimed to compare the incidence, clinical characteristics, and outcomes of irLI between receiving ICIs for hepatocellular carcinoma (HCC) vs. other solid tumours.
Background Systemic immune activation, hallmarked by C-reactive protein (CRP) and interleukin-6 (IL-6), can modulate antitumor responses. In this study, we evaluated the role of IL-6 CRP in stratification patients with non-small cell lung cancer (NSCLC) treated checkpoint inhibitors (ICIs). We also interrogated underlying immunosuppressive mechanisms driven IL-6/CRP axis. Methods cohort A (n=308), estimated association baseline objective response rate (ORR), progression-free survival (PFS),...
While deemed potentially curative, surgical resection of hepatocellular carcinoma (HCC) is associated with >70% risk post-operative relapse. Recurrence uniquely multifactorial in HCC, stemming from metachronous re-occurrence the original tumor or de novo cancerization. Circulating DNA may improve personalized stratification post-resection, a setting where adjuvant immunotherapy has failed to provide survival benefits.
Background Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its long-term efficacy remains sparse. Methods This study assessed 5-year outcomes of first-line pembrolizumab in a large, multicenter, cohort patients NSCLC and PD-L1 TPS≥50%, referred to as Pembro-real 5Y. Individual patient-level (IPD) from the experimental arm...
<p>Tumour micron-environment transcriptome analysis.</p>
Guidelines historically recommended mono-chemotherapy for the 1stline treatment of elderly/ECOG–PS 2 pts with NSCLC. Nowadays, there is no clear indication whether chemo-IO combinations can be effectively delivered in this population. We collected induction chemotherapy NSCLC treated carboplatin (c) -based chemo-P regimens, to compute received dose intensity (RDI) standard (s) and modified (m) regimens due age, comorbidities PS. Comorbidities were stratified according...
2607 Background: Mechanistic evidence suggests opioid signaling to modulate anti-tumor immunity. Whether opioids exposure may affect outcome of patients (pts) treated with immune checkpoint inhibitors is unproven, clinical being flawed by the negative associative bias between pain and higher burden disease. Methods: We conducted a post-hoc analysis phase 3 OAK (NCT02008227) 2 POPLAR (NCT01903993) trials, which randomized (1:1) pts advanced NSCLC receive either atezolizumab or docetaxel....
Guidelines historically recommended mono-chemotherapy for the 1st line treatment of elderly patients with non-small cell lung cancer (NSCLC) and poor performance status (PS). Nowadays, there is no clear indication whether chemo-immunotherapy (chemo-IO) combinations can be effectively delivered in this population. We collected induction chemotherapy data consecutive advanced NSCLC treated carboplatin-based regimens plus pembrolizumab, to compute received dose intensity (RDI) from standard or...
<h3>Background</h3> Pembrolizumab monotherapy is established as an effective front-line treatment for advanced non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50%. However, real-world data on its long-term efficacy remains sparse. <h3>Methods</h3> This study assessed 5-year outcomes of first-line pembrolizumab in a large, multicenter, cohort patients NSCLC and TPS Individual patient-level (IPD) from the experimental arm Keynote-024 trial were extracted (KN024 IPD...
<p>Kaplan-Meier survival estimates according to the receipt of no diabetes medication, other medications/insulin therapy only, and metformin (either alone or in combinations). A) Overall Survival whole cohort; patients not receiving medications: 18.9 months (95%CI: 15.9-21.6; 684 events), on only: 19.3 11.6-22.9; 48 metformin: 12.3 9.8-15.9; 100 events). B) Progression Free 8.2 7.1-9.4; 872 10.7 6.7-11.6; 61 7.9 5.1-10.1; 124 events).</p>
<p>Kaplan-Meier survival estimates according to the receipt of other diabetes medications and insulin therapy. A) Overall Survival whole cohort; patients on oral antidiabetic drugs therapy: 17.5 months (95%CI: 12.8-20.9; 82 events), not receiving therapy 17.8 15.4 – 19.7; 750 events). B) Progression Free 8.2 6.2-11.4; 106 8.1 7.1 9.2; 951 events).</p>
<p>Kaplan-Meier survival estimates according to the receipt of metformin. A) Overall Survival whole cohort; patients on metformin: 12.4 months (95%CI: 10.5-16.3; 100 events), not receiving 19.0 16.4 – 21.1; 732 events). B) Progression Free 7.9 5.3-10.1; 124 8.3 7.3 9.5; 933 events).</p>